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Abstract
Clinical trials revealed beneficial effects of the broad-spectrum serine protease inhibitor aprotinin on the prevention of
ischemia-reperfusion (I/R) injury. The underlying mechanisms remained largely unclear. Using in vivo microscopy on the
cremaster muscle of male C57BL/6 mice, aprotinin as well as inhibitors of the serine protease plasmin including tranexamic
acid and e-aminocaproic acid were found to significantly diminish I/R-elicited intravascular firm adherence and (subsequent)
transmigration of neutrophils. Remodeling of collagen IV within the postischemic perivenular basement membrane was
almost completely abrogated in animals treated with plasmin inhibitors or aprotinin. In separate experiments, incubation
with plasmin did not directly activate neutrophils. Extravascular, but not intravascular administration of plasmin caused a
dose-dependent increase in numbers of firmly adherent and transmigrated neutrophils. Blockade of mast cell activation as
well as inhibition of leukotriene synthesis or antagonism of the platelet-activating-factor receptor significantly reduced
plasmin-dependent neutrophil responses. In conclusion, our data suggest that extravasated plasmin(ogen) mediates
neutrophil recruitment in vivo via activation of perivascular mast cells and secondary generation of lipid mediators.
Aprotinin as well as the plasmin inhibitors tranexamic acid and e-aminocaproic acid interfere with this inflammatory cascade
and effectively prevent postischemic neutrophil responses as well as remodeling events within the vessel wall.
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Introduction
Ischemia-reperfusion (I/R) injury is still the most common cause
for organ dysfunction and failure after myocardial infarction,
hemorrhagic shock, and transplantation. Neutrophil recruitment
from the microvasculature to the perivascular tissue is a hallmark
in the pathogenesis of I/R injury [1]. In this process, a variety of
adhesion molecules, chemokines, and proteases have been
implicated strictly controlling the single steps of leukocyte
extravasation including rolling, firm adherence, and transendothe-
lial migration [2,3].
Plasmin is a serine protease which is released from the liver into
the systemic circulation as the zymogen plasminogen. In addition
to its well-known fibrinolytic properties, this protease has also been
reported to play a critical role in various other physiological and
pathophysiological processes including angiogenesis, wound heal-
ing, and inflammation. In this context, plasmin is suggested to
initiate intracellular signaling pathways as well as to activate
extracellular matrix (ECM) degrading enzymes ultimately facili-
tating cell adhesion and migration [4–6].
Despite recent concerns about the safety of the broad-spectrum
serine protease inhibitor aprotinin [7–9], clinical trials revealed
beneficial effects of this naturally occurring substance for the
prevention of postischemic organ dysfunction [10–12]. Here,
aprotinin has been suggested to suppress the transcription of genes
which have been implicated in the evolution of the postischemic
inflammatory response [13,14]. The consequences for each single
step of the leukocyte recruitment process during I/R, however,
have not yet been studied.
Previous studies have implicated the serine protease plasmin
as well as plasminogen activators in the regulation of leukocyte
migration to the site of inflammation [4–6]. Interestingly, lysine
analogues such as tranexamic acid or e-aminocaproic acid have
recently been reported to effectively and safely inhibit plasmin
activity [7–9,15]. The effect of these synthetic plasmin
inhibitors on postischemic leukocyte responses has not yet
been evaluated.
In the early reperfusion phase, remodeling processes within the
perivenular basement membrane have been described which are
thought to compromise microvascular integrity and to pave the
way for the excessive leukocyte infiltration of reperfused tissue
[16]. Due to its capability to disintegrate components of the
venular basement membrane as well as to activate other ECM-
degrading proteases, plasmin has been implicated in these events
[6]. The effect of plasmin inhibitors and aprotinin on remodeling
processes within the postischemic vessel wall has not yet been
investigated.
Therefore, the objective of the present study was i) to
systematically analyze the effect of the plasmin inhibitors
tranexamic acid and e-aminocaproic acid as well as of the
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step of the extravasation process of leukocytes as well as on
remodeling events within the perivenular basement membrane
during I/R and ii) to characterize the mechanisms underlying
plasmin-dependent leukocyte responses in vivo.
Results
Effect of tranexamic acid, e-aminocaproic acid, and
aprotinin on postischemic leukocyte responses
By using near-infrared reflected-light oblique transillumination
(RLOT) in vivo microscopy on the mouse cremaster muscle, effects
of the plasmin inhibitors tranexamic acid and e-aminocaproic acid
as well as of the broad-spectrum serine protease inhibitor aprotinin
on postischemic rolling, firm adherence, and transmigration of
leukocytes were analyzed (Fig. 1A).
As is well known, surgical preparation of the cremaster muscle
induced leukocyte rolling in postcapillary venules. After 30 min of
ischemia and 60 min of reperfusion, there was a significant
increase in numbers of rolling leukocytes as compared to sham-
operated animals which returned to baseline values after 120 min
of reperfusion. Treatment with tranexamic acid, e-aminocaproic
acid, or aprotinin did not significantly alter leukocyte rolling
during the entire reperfusion phase (Fig. 1B).
Under baseline conditions prior to I/R, few leukocytes were
found firmly adherent to the vessel wall of postcapillary venules
(8.662.0/10
4 mm
2). In contrast, after 30 min of ischemia and
120 min of reperfusion, there was a significant elevation in
numbers of firmly adherent leukocytes (22.662.6/10
4 mm
2)a s
compared to sham-operated controls (11.761.2/10
4 mm
2) This
elevation was significantly reduced in animals treated with
tranexamic acid (16.162.4/10
4 mm
2)o re-aminocaproic acid
(13.863.1/10
4 mm
2) and almost completely abolished in aproti-
nin-treated (11.962.2/10
4 mm
2) animals (Fig. 1C).
Prior to I/R, only few transmigrated leukocytes were detected
within the perivascular tissue (8.361.3/10
4 mm
2). In response to
I/R (30/120 min), the number of transmigrated leukocytes was
significantly increased (30.162.3/10
4 mm
2) as compared to sham-
operated controls (14.060.7/10
4 mm
2). Similar to our results for
leukocyte firm adherence, the postischemic increase in leukocyte
transmigration was significantly attenuated in mice treated with
tranexamic acid (17.063.4/10
4 mm
2) and completely abrogated in
e-aminocaproic acid- (12.261.5/10
4 mm
2) or aprotinin-treated
mice (12.862.0/10
4 mm
2). Similar results for leukocyte firm
adherence and transmigration were found already after 60 min
of reperfusion (Fig. 1D).
Effect of tranexamic acid, e-aminocaproic acid, and
aprotinin on postischemic remodeling of the perivenular
basement membrane
To characterize the expression profile of collagen IV within the
perivascular basement membrane, immunofluorescence staining
and confocal laser scanning microscopy were performed in tissue
samples of the cremaster muscle. In unstimulated animals, a
discontinuous expression of collagen IV was detected in postcap-
illary venules (Fig. 2A). Analysis of intensity profiles demonstrated
regions of low fluorescence intensity (less than 60% of average
fluorescence intensity/unit area of the entire vessel segment).
These low-expression regions (LER) were detected at a density of
6.060.1610
3/mm
2 (Fig. 2C) and had an average size of
6.860.4 mm
2 (Fig. 2B). Interestingly, I/R did not alter the
average density of these collagen IV LER, but caused a significant
enlargement of the average site size of collagen IV LER
(13.360.4 mm
2). This enlargement was almost completely abol-
ished in mice treated with tranexamic acid (7.960.2 mm
2), e-
aminocaproic acid (6.860.6 mm
2), or aprotinin (6.960.2 mm
2).
Effect of tranexamic acid, e-aminocaproic acid, and
aprotinin on postischemic microvascular leakage in the
initial reperfusion phase
As a measure of microvascular permeability, leakage of FITC
dextran to the postischemic cremaster muscle was analyzed
(Fig. 3A). In the initial reperfusion phase, there was a time-
dependent, significant increase in the leakage of FITC dextran as
compared to sham-operated controls. This increase did not
significantly differ from that observed in mice treated with the
plasmin inhibitors tranexamic acid or e-aminocaproic acid, with
the broad-spectrum serine protease inhibitor aprotinin, with an
inhibitor of mast cell degranulation (cromolyn), or in mast cells-
depleted mice (Fig. 3B).
Mast cell activation in response to I/R
As a measure of mast cell activation in vivo, ruthenium red
staining of the cremaster muscle was performed (Fig. 4A). In
response to I/R (30/120 min), there was a significant elevation
(702.3643.3%) in the number of ruthenium red-positive cells as
compared to sham-operated animals. This elevation was almost
completely abolished in animals treated with an inhibitor of mast
cell degranulation (cromolyn; 31.7620.2%) as well as with the
plasmin inhibitors tranexamic acid (75.0630.5%) and e-amino-
caproic acid (10.2631.1%), or with the serine protease inhibitor
aprotinin (6.9618.6%). Blockade of the PAF receptor (BN52021;
469.3654.1%) or inhibition of leukotriene synthesis (MK-886;
506.86126.7%) only partially reduced the number of cremasteric
ruthenium red-positive cells (Fig. 4B). As a positive control,
treatment with compound 48/80 (CMP 48/80) strongly enhanced
the number of ruthenium red-positive mast cells (1214.86219.8%)
as compared to unstimulated controls. Conversely, in mast cell-
depleted mice only few single ruthenium red-positive mast cells
were detected (data no shown).
Role of mast cells, leukotrienes, and platelet-activating
factor on postischemic leukocyte responses
In further experiments, the effect of mast cell depletion, of an
inhibitor of mast cell degranulation (cromolyn), of an inhibitor of
leukotriene synthesis (MK-886), and of a PAF receptor antagonist
(BN52021) on postischemic rolling, firm adherence, and transmi-
gration of leukocytes was analyzed. Whilst mast cell depletion or
treatment with cromolyn, MK-886, or BN52021 did not
significantly alter the number of leukocytes rolling in postcapillary
venules of the postischemic cremaster muscle (data not shown), the
I/R (30/120 min)-elicited elevation in numbers of firmly adherent
(Fig. 4C) and (subsequently) transmigrated (Fig. 4D) leukocytes
was significantly reduced. Similar results for leukocyte firm
adherence and transmigration were obtained already after
60 min of reperfusion.
Effect of plasmin on surface expression of CD11b and
CD62L on neutrophils
The effect of plasmin on the expression of adhesion molecules
CD11b/Mac-1 and CD62L/L-selectin on murine neutrophils was
analyzed by flow cytometry (Fig. 5). Co-incubation with plasmin
(for all concentrations analyzed) did not significantly alter the
expression of CD11b/Mac-1 and CD62L/L-selectin on the
surface of murine neutrophils isolated from the peripheral blood
as compared to unstimulated controls. In contrast, the potent
neutrophil stimulant PMA was able to significantly enhance cell
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selectin.
Effect of intravascular vs. extravascular application of
plasmin on leukocyte rolling, firm adherence, and
transmigration
To further investigate the mode of action of plasmin in vivo,
murine plasmin was applied either to the vascular compartment
(intraarterial injection) or to the extravascular compartment
(intrascrotal injection). Intravascular administration of plasmin
did not alter rolling, firm adherence, and transmigration of
leukocytes as compared to controls (at all concentrations
investigated; Fig. 6A, C, E). Interestingly, extravascularly applied
plasmin did not alter leukocyte rolling, but induced a dose-
dependent increase in numbers of firmly adherent and transmi-
grated leukocytes as compared to vehicle-treated controls (Fig. 6B,
D, F). Since a dose of 2.0 mg was able to elicit a robust elevation in
firm adherence and (subsequent) transmigration of leukocytes, this
concentration was used in further experiments.
Figure 1. Effect of TXA, EACA, and aprotinin on postischemic leukocyte responses. Postcapillary venules in the postischemic cremaster
muscle treated with e-aminocaproic acid (EACA) or vehicle (A; scale bar 25 mm). Leukocyte rolling (B), firm adherence (C), and transmigration (D) in
mice treated with tranexamic acid (TXA), EACA, or aprotinin undergoing I/R (mean6SEM; n=6 per group; #p,0.05, vs. sham; *p,0.05, vs. vehicle).
doi:10.1371/journal.pone.0017229.g001
Figure 2. Effect of TXA, EACA, and aprotinin on postischemic
remodeling of the perivenular basement membrane. Postcapil-
lary venule in the postischemic cremaster muscle immunostained for
collagen IV. White rings show low-expression regions (LER; A; scale bar
10 mm). Size (B) and density (C) of LER in mice treated with TXA, EACA,
or aprotinin undergoing I/R (mean6SEM; n=4 per group; #p,0.05, vs.
unstimulated; *p,0.05, vs. vehicle).
doi:10.1371/journal.pone.0017229.g002
Figure 3. Effect of TXA, EACA, and aprotinin on postischemic
microvascular leakage. FITC dextran leakage in the postischemic
cremaster muscle (A; scale bar 100 mm). FITC dextran leakage in mice
treated with TXA, EACA, aprotinin, or cromolyn as well as in mast cell-
depleted mice undergoing I/R (B; mean6SEM for n=4 per group;
#p,0.05, vs. sham).
doi:10.1371/journal.pone.0017229.g003
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In separate experiments, mast cell activation was analyzed upon
stimulation with plasmin. Four hours after intrascrotal injection of
plasmin, the number of cremasteric ruthenium red-positive cells
was significantly increased (115.9624.9%) as compared to
unstimulated controls (Fig. 7A). This increase was almost
completely abolished in cromolyn-treated animals (6.5613.0%),
but only partially reduced in animals treated with MK-886
(57.668.1%) or BN52021 (28.568.9%). In mast cell-depleted
animals, only few single ruthenium red-positive cells were detected
(data not shown).
Effect of plasmin on tissue expression of 5-lipoxygenase
and lyso-PAF-acetyltransferase
Using RT-PCR, the effect of plasmin on RNA expression of 5-
lipoxygenase (5-LO) and lyso-PAF-acetyltransferase (LPCAT),
enzymes facilitating the synthesis of leukotrienes and PAF,
respectively, was analyzed in the mouse cremaster muscle. In
response to plasmin, RNA expression of 5-LO (331.8623.1%) and
LPCAT (484.3668.4%) was strongly enhanced as compared to
unstimulated controls (data not shown).
Role of mast cells for plasmin-elicited leukocyte
responses
Using near-infrared RLOT in vivo microscopy on the cremaster
muscle, the effect of mast cell deficiency or treatment with the
mast cell stabilizer cromolyn on plasmin-elicited leukocyte
responses was analyzed. Four hours after intrascrotal injection of
plasmin, no significant differences were observed in numbers of
rolling leukocytes among all experimental groups (data not shown).
In contrast, the numbers of firmly adherent (13.761.7/10
4 mm
2)
and (subsequently) transmigrated leukocytes (16.362.2/10
4 mm
2)
were found to be significantly increased upon stimulation with
plasmin as compared to unstimulated controls (5.360.9/10
4 mm
2;
Figure 4. Role of mast cells and lipid mediators for postischemic leukocyte responses. Cremasteric ruthenium-red-positive mast cells (A;
arrows). The number of ruthenium red-positive cells in mice treated with TXA, EACA, aprotinin, cromolyn, MK-886, or BN52021 undergoing I/R (B).
Leukocyte firm adherence (C) and transmigration (D) in mast cell-depleted mice as well as in mice treated with cromolyn, BN52021, or MK-886
undergoing I/R (mean6SEM for n=4–5 per group; #p,0.05, vs. sham; *p,0.05, vs. vehicle).
doi:10.1371/journal.pone.0017229.g004
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4 mm
2). This increase was almost completely abolished
in animals treated with cromolyn (4.661.0/10
4 mm
2; 7.360.7/
10
4 mm
2) or in mast cell-depleted animals (5.860.4/10
4 mm
2;
8.460.6/10
4 mm
2; Fig. 7B, D).
Role of leukotrienes and platelet-activating-factor for
plasmin-elicited leukocyte responses
To characterize the role of secondarily generated lipid
mediators in plasmin-elicited leukocyte responses, the PAF
receptor antagonist BN52021 as well as the inhibitor of leukotriene
synthesis MK-886 was used. No significant differences were
detected among all experimental groups in numbers of rolling
leukocytes (data not shown). In contrast, four hours after
intrascrotal injection of plasmin, there was a significant increase
in the number of firmly adherent leukocytes (17.061.2/10
4 mm
2)
and transmigrated leukocytes (18.460.8/10
4 mm
2) as compared to
unstimulated controls (5.360.9/10
4 mm
2; 6.961.3/10
4 mm
2). This
increase was found to be significantly diminished in animals
treated with MK-886 (12.161.4/10
4 mm
2; 11.060.9/10
4 mm
2)o r
BN52021 (7.161.4/10
4 mm
2; 8.460.4/10
4 mm
2; Fig. 7C, E).
Phenotyping of transmigrated leukocytes
To identify the phenotype of transmigrated leukocytes,
immunostaining for CD45 (common leukocyte antigen), Ly-6G
(neutrophils), and F4/80 (monocytes/macrophages) of cremasteric
tissue samples was performed. In response to I/R as well as upon
intrascrotal injection of plasmin, over 80% of transmigrated
leukocytes were positive for Ly-6G and about 20% of transmi-
grated leukocytes were positive for F4/80, respectively (Tab. 1).
Microhemodynamic parameters and systemic leukocyte
counts
To assure intergroup comparability, quantification of inner
vessel diameters, blood flow velocities, and wall shear rates of
analyzed postcapillary venules as well as systemic leukocyte counts
was performed (Tab. 2). No significant differences were detected
among all experimental groups.
Expression of the plasmin(ogen) receptor histone protein
H2B on BMMCs
Using flow cytometry as well as immunostaining and confocal
laser scanning microscopy, expression of the major plasmin(ogen)
receptor histone protein H2B was detected on the surface of bone
marrow-derived mast cells (BMMCs; data not shown).
Discussion
Restoration of blood flow is the overall goal for successful organ
transplantation as well as for the treatment of myocardial
infarction, hemorrhagic shock, and stroke. As a consequence of
this inevitable approach, however, neutrophils accumulate within
the postischemic microvasculature and compromise reperfusion of
the affected organ. Subsequently, transmigrating neutrophils
release reactive oxygen species, cytokines, and proteases, impairing
microvascular integrity and promoting postischemic tissue injury
[1]. Notably, extravasated neutrophils also contribute to tissue
healing and regeneration [17] collectively emphasizing neutrophil
recruitment as a key event in the pathogenesis of I/R injury.
Using different animal models, the serine protease plasmin as
well as plasmin activators have been implicated particularly in the
migration of monocytes, but also in the recruitment of neutrophils
[4–6]. Moreover, clinical trials revealed beneficial effects of the
broad-spectrum serine protease inhibitor aprotinin for the
prevention of postischemic organ dysfunction after coronary
revascularization [10–12]. In this context, aprotinin has been
reported to suppress the transcription of genes which are supposed
to play a major role in the postischemic inflammatory response
[13,14]. The resulting consequences for each single step of the
leukocyte recruitment process, however, remained unclear.
Figure 5. Effect of plasmin on neutrophil activation. Fluorescence histograms for expression of CD11b/Mac-1 and CD62L/L-selectin on murine
neutrophils undergoing stimulation with plasmin, PMA (open histograms, broken lines), or vehicle (open histograms, solid lines) as compared to
control IgG (solid histograms).
doi:10.1371/journal.pone.0017229.g005
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17229Figure 6. Effect of plasmin on leukocyte rolling, firm adherence, and transmigration. Leukocyte responses in the cremaster muscle after
intraarterial (A, C, E) or intrascrotal (B, D, F) injection of plasmin (mean6SEM for n=3 per group; *p,0.05, vs. control).
doi:10.1371/journal.pone.0017229.g006
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PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17229Figure 7. Role of mast cells and lipid mediators for plasmin-dependent leukocyte responses. The number of ruthenium red-positive cells in
the cremaster muscle of mice treated with cromolyn, MK-886, or BN52021 undergoing stimulation with plasmin (A). Leukocyte responses in the
cremaster muscle of mast cell-depleted mice as well as of mice treated with cromolyn (B, D), MK-886, BN52021 (C, E), or vehicle undergoing stimulation
with plasmin (mean6SEM for n=4–6 per group; #p,0.05, vs. unstimulated; *p,0.05, vs. vehicle; 1p,0.05, vs. MK-886; up,0.05, vs. cromolyn).
doi:10.1371/journal.pone.0017229.g007
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cremaster muscle, we systematically analyzed the effects on
postischemic rolling, firm adherence, and transmigration of
leukocytes of the broad-spectrum serine protease inhibitor
aprotinin, a naturally occurring bovine protein, as well as of the
synthetic plasmin inhibitors tranexamic acid and e-aminocaproic
acid. Our experimental data demonstrate that aprotinin as well as
the plasmin inhibitors do not significantly alter leukocyte rolling in
the early reperfusion phase. In contrast, firm adherence and
(subsequent) transmigration of neutrophils to the postischemic
tissue was found to be significantly diminished in animals treated
with tranexamic acid, e-aminocaproic acid, or aprotinin. These
findings are in agreement with previous observations as elevated
myeloperoxidase levels in the postischemic myocardium were
significantly reduced upon treatment with aprotinin [13,14]. It is
interesting that aprotinin as well as the plasmin inhibitors
suppressed postischemic neutrophil recruitment already on the
level of intravascular adherence whilst under different inflamma-
tory conditions (e.g. stimulation with fMLP, LTB4, or IL-1b)
aprotinin has been reported to selectively diminish transendothe-
lial migration of neutrophils [18–20]. Consequently, these data
point to a stimulus-specific effect of aprotinin on the single steps of
the extravasation process of neutrophils.
Recently, remodeling processes within the postischemic vessel
wall have been described which are thought to be critically
involved in the pathogenesis of I/R injury [16]. Specifically, there
are regions within the basement membrane of postcapillary
venules where the expression of collagen IV, a main structural
component of venular basement membranes, is significantly lower
than the average vascular level [16,18]. In response to I/R, these
low-expression regions (LERs) of collagen IV become strongly
enlarged thereby compromising microvascular integrity as well as
Table 1. Phenotyping of transmigrated leukocytes was
performed by immunostaining for CD45 (common leukocyte
antigen), Ly-6G (neutrophils), and F4/80 (monocytes/
macrophages) of cremasteric tissue samples as detailed in
Material and Methods (mean6SEM for n=6 per group).
Ly-6G
+ cells
(% of CD45
+ cells)
F4/80
+ cells
(% of CD45
+ cells)
I/R 83.560.1 18.360.1
Plasmin 83.360.1 22.560.1
doi:10.1371/journal.pone.0017229.t001
Table 2. Systemic leukocyte counts as well as microhemodynamic parameters, including inner vessel diameter, blood flow
velocity, and wall shear rate were obtained as detailed in Material and Methods (mean6SEM for n=3–6 per group).
Inner diameter [mm] Vmean [mm/s] Wall shear rate [s-1]
Systemic leukocyte
counts [x 10
6 ml
21]
I/R sham 25.660.3 1.260.1 1782.76136.7 2.260.4
vehicle 25.960.2 1.260.1 1978.96166.3 2.560.5
TXA 25.960.4 1.360.2 1875.0650.7 3.260.7
EACA 26.060.5 1.460.1 1740.8669.3 2.960.4
aprotinin 25.860.3 1.360.1 1961.8690.3 3.460.7
I/R sham 25.961.1 1.360.1 2011.6671.3 3.261.1
vehicle 26.160.4 1.360.1 2011.1682.0 3.160.6
MK-886 25.060.8 1.260.1 1923.86214.3 3.060.7
BN 52021 24.061.0 1.160.1 1903.66397.4 3.361.5
cromolyn 24.260.6 1.160.1 1827.26137.0 3.560.4
mast cell
depletion
24.260.7 1.360.1 2165.8643.0 3.660.7
plasmini.a. control 26.160.4 1.560.1 2217.16231.3 4.661.1
0.2 mg 26.060.1 1.260.1 1856.0669.1 4.861.0
2.0 mg 25.660.2 1.460.1 2103.86106.2 3.860.8
20.0 mg 26.160.4 1.460.1 2124.4639.5 4.960.6
plasmini.s. control 26.061.5 1.560.1 1689.56122.8 2.960.9
0.02 mg 25.960.4 1.260.1 1766.16183.4 5.061.3
0.2 mg 26.560.4 1.360.1 1879.1655.2 5.860.8
2.0 mg 25.260.4 1.160.1 1740.36160.4 7.762.0
plasmini.s. control 26.260.8 1.360.1 1972.86150.3 4.861.1
vehicle 26.060.4 1.360.1 1929.9653.4 5.461.3
BN 52021 26.060.2 1.360.1 2023.36115.7 5.960.8
MK-886 26.060.4 1.360.1 1995.9683.5 3.160.5
cromolyn 26.460.5 1.360.1 1920.96197.8 5.160.9
mast cell
depletion
25.260.6 1.360.1 2047.1669.1 3.660.6
doi:10.1371/journal.pone.0017229.t002
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Interestingly enough, treatment with tranexamic acid, e-amino-
caproic acid, or aprotinin almost completely abolished these
postischemic remodeling events within the perivenular basement
membrane and might thereby significantly contribute to the
prevention of I/R injury. Whether these effects of the plasmin
inhibitors are the result of a direct inhibition of plasmin-mediated
degradation of collagen IV (e.g. by inhibiting plasmin activity on
the surface of transmigrating neutrophils or in the extravasating
plasma) or the consequence of diminished firm adherence and
(subsequent) transmigration of neutrophils cannot clearly be
answered in this in vivo study. Collectively, our experimental data
demonstrate that the plasmin inhibitors tranexamic acid and e-
aminocaproic acid as well as the broad-spectrum serine protease
inhibitor aprotinin effectively prevent intravascular firm adher-
ence as well as (subsequent) transmigration of neutrophils to the
reperfused tissue and protect the microvasculature from postis-
chemic remodeling events. Notably, treatment with aprotinin has
recently been reported to be associated with transient renal
failure and other complications in critically ill patients [7–9]. In
consideration of the comparatively mild side effects, the strong
anti-inflammatory potency, and the considerably low costs of the
lysine analogues tranexamic acid and e-aminocaproic acid, the
use of these drugs might be favored for the prevention of I/R
injury.
Although the effects of aprotinin and the plasmin inhibitors on
postischemic neutrophil responses as well as on remodeling events
within the vessel wall have now been elucidated, the mechanisms
underlying plasmin-dependent neutrophil recruitment in vivo
remain poorly understood. Plasmin(ogen) is primarily generated
in the liver and subsequently released into the systemic circulation
where it is known to play a major role in the fibrinolytic system
[4–6]. Our in vivo data demonstrate that intravascularly circulating
plasmin is not able to induce significant leukocyte responses.
In this context, physiological plasmin antagonists such as a2-
antiplasmin are thought to minimize excessive proteolytic activity
of plasmin within the vascular compartment and might thereby
prevent inflammatory effects of this protease under physiological
conditions. In the initial reperfusion phase, however, permeability
of the postischemic microvasculature rapidly increases enabling
plasmin(ogen) to extravasate to the perivascular tissue. Interest-
ingly, extravascular administration of plasmin caused a dose-
dependent elevation in numbers of firmly adherent and transmi-
grated neutrophils. Our results confirm previous observations as
intrastriatal injection of plasmin has been reported to induce
neutrophil infiltration of the brain [21]. Consequently, these data
indicate that intravascularly circulating plasmin(ogen) does not
exert inflammatory effects until it extravasates to the perivascular
tissue. Moreover, we found that incubation with plasmin did not
alter surface expression of CD11b/Mac-1 and CD62L/L-selectin
on murine neutrophils suggesting that plasmin is not able to
directly activate neutrophils. Notably, it cannot be excluded that
I/R creates a favorable environment for direct actions of plasmin
on neutrophils and it might also be possible that plasmin is able to
induce affinity changes of integrins ultimately facilitating extrav-
asation of neutrophils. In addition, it might be possible that
receptor-bound plasminogen presented on the surface of circulat-
ing leukocytes might already be activated within the vascular
compartment during I/R and might thereby contribute to
leukocyte extravasation as hypothetized by previous in vitro studies
[5,6].
Because of their close vicinity to the vascular endothelium and
their ability to generate an abundance of inflammatory mediators
(e.g. leukotrienes and PAF), tissue mast cells are considered as key
players in the postischemic inflammatory response [22,23]. In this
context, it is worth to be noted that the involvement of mast cells
might be variable in different organs since tissue specific diversity
in the phenotype, density, and distribution of mast cells has
previously been reported [24]. In our experiments, we found that
treatment with aprotinin as well as with the plasmin inhibitors
almost completely prevents postischemic activation of mast cells.
Furthermore, we demonstrate that plasmin is able to activate
perivascular mast cells in vivo extending previous observations as
plasmin has been reported to directly activate cultured mast cells
[25]. In line with these results, we also show that blockade of mast
cell activation almost completely abolished plasmin-dependent
intravascular firm adherence and (subsequent) transmigration of
neutrophils. Moreover, it is interesting that treatment with
aprotinin or with the plasmin inhibitors as well as blockade of
mast cell activation did not affect microvascular leakage in the
early reperfusion phase. Accordingly, interaction of extravasated
plasminogen with plasminogen receptors (e.g. histone protein H2B
[26]) on perivascular mast cells is suggested to accelerate the
conversion of plasminogen to plasmin, to protect plasmin from
inactivation by endogenous inhibitors, and to enhance the
biological activity of this protease [5,6]. Collectively, these data
indicate a divergent role of plasmin in the regulation of
postischemic leukocyte recruitment and microvascular permeabil-
ity and, moreover, strongly suggest that extravasated plasmin(o-
gen) mediates neutrophil recruitment in vivo indirectly via
activation of perivascular mast cells.
Following recent in vitro studies, surface-bound plasmin is
supposed to specifically interact with different cell-surface
receptors (e.g. protease-activated receptors, integrins, annexin
A2) [27,28], to activate intracellular signaling pathways [29], and
to induce the generation of inflammatory mediators [30,31]. Here,
we demonstrate that plasmin is able to induce the expression of 5-
lipoxygenase and lyso-PAF-acetyltransferase, key enzymes controlling
the synthesis of leukotrienes and PAF, respectively. Moreover,
inhibition of leukotriene synthesis or blockade of the PAF receptor
significantly diminished plasmin-dependent firm adherence and
(subsequent) transmigration of neutrophils. Thus, our results
indicate that plasmin facilitates neutrophil extravasation in vivo
via endogenous generation of lipid mediators. Consequently, in
the early reperfusion phase, extravasated plasmin(ogen) is
suggested to induce the generation of leukotrienes and PAF
which, in turn, directly activate neutrophils [32] and promote
intravascular adherence as well as (subsequent) transmigration of
these inflammatory cells in postischemic tissue. Since inhibition of
leukotriene synthesis or blockade of the PAF receptor only
partially reduced plasmin- as well as I/R-elicited activation of
mast cells, the postischemic generation of lipid mediators is, at
least in part, suggested to occur downstream of mast cell
activation.
In conclusion, our experimental data suggest that extravasated
plasmin(ogen) mediates firm adherence and (subsequent) transmi-
gration of neutrophils to the reperfused tissue indirectly through
activation of perivascular mast cells and a sequential generation of
leukotrienes and PAF. The plasmin inhibitors tranexamic acid and
e-aminocaproic acid as well as the broad-spectrum serine protease
inhibitor aprotinin are thought to interfere with this inflammatory
cascade and effectively prevent intravascular accumulation and
(subsequent) transmigration of neutrophils to the reperfused tissue
as well as protect the microvasculature from postischemic
remodeling events. These findings provide novel insights into the
mechanisms underlying the postischemic inflammatory response
and highlight the use of plasmin inhibitors as a potential
therapeutic approach for the prevention of I/R injury.
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Animals
Male C57BL/6 mice were purchased from Charles River
(Sulzfeld, Germany). All experiments were performed with male
mice at the age of 10–12 weeks. Animals were housed under
conventional conditions with free access to food and water. All
experiments were performed according to German legislation for
the protection of animals (approved by the government of Upper
Bavaria; permit number 55.2-1-54-2531-84/09).
Surgical procedure
The surgical preparation was performed as originally described
by Baez with minor modifications [33,34]. Mice were anesthetized
using a ketamine/xylazine mixture (100 mg/kg ketamine and
10 mg/kg xylazine), administrated by i.p. injection. The right
carotid and the left femoral artery were cannulated in a retrograde
manner for continuous blood pressure monitoring and for
administration of microspheres and drugs (see below). The right
cremaster muscle was exposed through a ventral incision of the
scrotum. The muscle was opened ventrally in a relatively avascular
zone, using careful electrocautery to stop any bleeding, and spread
over the transparent pedestal of a custom-made microscopy stage.
Epididymis and testicle were detached from the cremaster muscle
and placed into the abdominal cavity. Throughout the procedure
as well as after surgical preparation during in vivo microscopy, the
muscle was superfused with warm-buffered saline.
In vivo microscopy
The setup for in vivo microscopy was centered around an
Olympus BX 50 upright microscope (Olympus Microscopy,
Hamburg, Germany), equipped for stroboscopic fluorescence
epi-illumination microscopy. Light from a 75-W xenon source
was narrowed to a near-monochromatic beam of a wavelength of
700 nm by a galvanometric scanner (Polychrome II, TILL
Photonics, Graefelfing, Germany) and directed onto the specimen
via a FITC filter cube equipped with dichroic and emission filters
(DCLP 500, LP515, Olympus). Microscopic images were obtained
with Olympus water immersion lenses [20x/numerical aperture
(NA) 0.5 and 10x/NA 0.3] and recorded with an analog black-
and-white charge-coupled device (CCD) video camera (Cohu
4920, Cohu, San Diego, CA, USA) and an analog video recorder
(AG-7350-E, Panasonic, Tokyo, Japan). Reflected light oblique
transillumination (RLOT) was obtained by positioning a mirroring
surface (reflector) directly below the specimen and tilting its angle
relative to the horizontal plane. The reflector consisted of a round
cover glass (thickness, 0.19–0.22 mm; diameter, 11.8 mm), which
was coated with aluminum vapor (Freichel, Kaufbeuren, Ger-
many) and brought into direct contact with the overlying specimen
as described previously [34]. For measurement of centerline blood
flow velocity, green fluorescent microspheres (0.96 mm diameter,
Molecular Probes, Leiden, The Netherlands) were injected via the
femoral artery catheter, and their passage through the vessels of
interest was recorded using the FITC filter cube under appropriate
stroboscopic illumination (exposure, 1 ms; cycle time, 10 ms;
l=488 nm), integrating video images for sufficient time (.80 ms)
to allow for the recording of several images of the same bead on
one frame. Beads that were flowing freely along the centerline of
the vessels were used to determine blood flow velocity (see below).
Quantification of leukocyte kinetics and
microhemodynamic parameters
For off-line analysis of parameters describing the sequential
steps of leukocyte extravasation, we used the Cap-Image image
analysis software (Dr. Zeintl, Heidelberg, Germany). Rolling
leukocytes were defined as those moving slower than the associated
blood flow and quantified for 30 s. Firmly adherent cells were
determined as those resting in the associated blood flow for more
than 30 s and related to the luminal surface per 100 mm vessel
length. Transmigrated cells were counted in regions of interest
(ROI), covering 75 mm on both sides of a vessel over 100 mm
vessel length. By measuring the distance between several images of
one fluorescent bead under stroboscopic illumination, centerline
blood flow velocity was determined. From measured vessel
diameters and centerline blood flow velocity, apparent wall shear
stress was calculated, assuming a parabolic flow velocity profile
over the vessel cross section.
Experimental groups
Animals were assigned randomly to the following groups: Sham-
operated mice, mast cell-depleted mice as well as mice treated with
tranexamic acid, e-aminocaproic acid, aprotinin, cromolyn, MK-
886, BN 52021, or drug vehicle undergoing I/R (30/120 min;
n=5–6). In another set of experiments, control mice received
vehicle or different doses of recombinant murine plasmin
administrated either by intraarterial (0.2, 2.0, and 20.0 mg; diluted
in 200 ml PBS supplemented with 0.01% BSA) or by intrascrotal
injection (0.02, 0.2, 2.0 mg; diluted in 200 ml PBS supplemented
with 0.01% BSA; n=3 each group). Additional experiments were
performed in control mice, mast cell-depleted mice as well as in
mice receiving either cromolyn, BN 52021, MK-886, or respective
drug vehicle undergoing intrascrotal stimulation with plasmin
(2.0 mg intrascrotally; n=6 each group).
Inhibitors and blocking antibodies
The following inhibitors were used: aprotinin (100.000 KIU
kg
21 i.a.; 5 min prior to onset of reperfusion as a bolus and then as
continuous infusion 100.000 KIU kg
21 h
21; Sigma-Aldrich, Dei-
senhofen, Germany) is a plasmin inhibitor [20]. BN 52021 (20 mg
kg
21 i.a.; Sigma-Aldrich) is a PAF receptor antagonist; cromolyn
(0.2 mg kg
21 i.a.; Sigma-Aldrich) is an inhibitor of mast cell
degranulation [35]; e-aminocaproic acid (100 mg kg
21 i.a. 5 min
prior to onset of reperfusion as a bolus and then as continuous
infusion 100 mg kg
21 h
21; Sigma-Aldrich) is a plasmin inhibitor
[36]; MK-886 (1 mg kg
21 i.a.; Sigma-Aldrich) is an inhibitor of
the 5-lipoxygenase activating protein (FLAP) hence blocking
leukotriene synthesis [37]; tranexamic acid (100 mg kg
21 i.a.
5 min prior to onset of reperfusion as a bolus and then as
continuous infusion 100 mg kg
21 h
21; Sigma-Aldrich) is a
plasmin inhibitor [38]. Control animals received equivalent
volumes of corresponding drug vehicles.
Mast cell depletion
Mast cell depletion was performed as described elsewhere
[39,40]. Briefly, wild-type animals were treated with CMP 48/80
(1 mg/kg i.p.; Sigma-Aldrich, Deisenhofen, Germany) 48 h prior
to experimentation. This approach has been observed previously
to deplete mast cell granules and to allow time for CMP48/80-
induced inflammation to dissipate.
Experimental protocols
In a first set of experiments, three postcapillary vessel segments
in a central area of the spread-out cremaster muscle were
randomly chosen among those that were at least 150 mm away
from neighboring postcapillary venules and did not branch over a
distance of at least 150 mm. After having obtained baseline
recordings of leukocyte rolling, firm adhesion, and transmigration
Plasmin Inhibitors Prevent Leukocyte Recruitment
PLoS ONE | www.plosone.org 11 February 2011 | Volume 6 | Issue 2 | e17229in all three vessel segments, ischemia was induced by clamping all
supplying vessels at the basis of the cremaster muscle using a
vascular clamp (Martin, Tuttlingen, Germany). Stagnancy of
blood flow was then verified by in vivo microscopy. After 30 min of
ischemia, the vascular clamp was removed and reperfusion was
restored for 140 min. Measurements, which took about 5 min,
respectively, were repeated at 60 and 120 min after onset of
reperfusion.
In a second set of experiments, leukocyte recruitment to the
cremaster muscle was analyzed either 240 min after intraarterial
(0.2, 2.0, or 20.0 mg) or 240 min after intrascrotal injection of
plasmin (0.02, 0.2, or 2.0 mg in 0.2 ml PBS, Molecular
Innovations, Novi, MI, USA). Five vessel segments were randomly
chosen in a central area of the spread-out cremaster muscle among
those that were at least 150 mm away from neighboring
postcapillary venules and did not branch over a distance of at
least 150 mm. After having obtained recordings of migration
parameters, blood flow velocity was determined as described
above. After in vivo microscopy, tissue samples of the cremaster
muscle were taken for immunohistochemistry. Blood samples were
collected by cardiac puncture for the determination of systemic
leukocyte counts using a Coulter ACT Counter (Coulter Corp.,
Miami, FL, USA). Anesthetized animals were then killed by
bleeding to death.
Bone marrow-derived mast cells
BMMCswerederived from8–12weekoldC57BL/6Jmice.Cells
from fresh bone marrow were resuspended in complete Iscove’s
Modified Dulbecco’s Medium (IMDM with 10% heat inactivated
fetal calf serum [HIFCS], 2 mM L-Glutamine [Gln], 1% Penicillin-
Streptomycin solution [PEST], 50 mM b-mercaptoethanol [b-ME],
and2 ng/mlrecombinantmurineIL-3fromPeprotech,RockyHill,
NJ) and cultured at 37uC, 5% CO2 for four days. Subsequently,
BMMCs were diluted weekly to 0.5610
6 cells/ml with a mixture of
80% fresh, complete IMDM and 20% recycled medium, with IL-3
added every 2
nd day. Nonadherent cells were monitored for the
presence of FceRI [with a phycoerythrin (PE)-conjugated hamster,
anti-mouse FceRIa antibody; clone MAR-1, eBioscience, San
Diego,CA)andc-kit(ratIgG2Banti-mouse CD117/c-kit;clone3c1,
ImmunoKontact, Bioggo, Switzerland) by FACS analysis.
Microvascular permeability
In separate experiments, leakage of the macromolecule FITC
dextran (5 mg in 0.1 ml saline, i.a., 5 min prior to induction of
reperfusion; Mr 150,000, Sigma-Aldrich) was analyzed in sham-
operated control mice as well as in mice receiving tranexamic acid,
e-aminocaproic acid, aprotinin, cromolyn, or drug vehicle
undergoing I/R (30/60 min). Five postcapillary vessel segments
as well as the surrounding perivascular tissue were excited at
488 nm, and emission .515 nm was recorded by a CCD camera
(Sensicam, PCO, Kelheim, Germany) within the 1
st minute of
reperfusion as well as 10, 20, 30, 40, 50, and 60 min after
induction of reperfusion using an appropriate emission filter (LP
515). Mean gray values of fluorescence intensity were measured by
digital image analysis (TILLvisION 4.0, TILL Photonics) in six
randomly selected ROIs (50x50 mm
2), localized 50 mm distant
from the postcapillary venule under investigation.
Confocal microscopy
For the analysis of collagen IV expression, cremaster muscles
were fixed in 4% paraformaldehyde. Tissues were then blocked
and permeabilized in PBS, supplemented with 10% goat serum
(Sigma-Aldrich) and 0.5% Triton X-100 (Sigma-Aldrich). After
incubation with the primary rabbit anti-mouse collagen IV
polyclonal antibody (Abcam, Cambridge, UK) at room temper-
ature for 12 h, tissues were incubated with the secondary Alexa
Fluor 488-linked goat anti-rabbit (Invitrogen, Carlsbad, CA, USA)
antibody for 3 h at room temperature.
Immunostained tissues were mounted in PermaFluor (Beckman
Coulter, Fullerton, CA, USA) on glass slides and observed using a
Leica SP5 confocal laser-scanning microscope (Leica Microsys-
tems, Wetzlar, Germany) with an oil immersion lens (Leica; 40x/
NA 1.25–0.75). Optical sections of tissue samples through the
whole depth of the tissue were obtained using, as far as possible,
the same settings for all samples analyzed. Z-stack digital images
were collected optically at every 0.5 mm depth and applied to
three-dimensional (3D) reconstruction analysis using Leica Appli-
cation Suite software. To analyze the expression profile of collagen
IV, 3D images of vessels were split in the middle along the
longitudinal axis. Images of these ‘‘semi-vessels’’ were then
analyzed for fluorescence intensity, as described previously
[16,18], using Leica Application Suite software. Briefly, ROIs
within 3D images of semi-vessels were identified manually, and
their intensity profile was compared with the average intensity of
the entire vessel within the same field of view. Collagen IV low-
expression regions (LER) were defined as those regions in which
the average fluorescence intensity/unit area was less than 60% of
the average fluorescence intensity in the whole vessel segment
under investigation. LE sites from three vessel segments/tissue
(n=4 mice per group) were analyzed. LE site size was determined
using Leica Application Suite software, and LE site density was
calculated for the total surface area of the semi-vessels.
Confocal microscopy on BMMCs was done after incubating the
cells with TO-PRO 3 (Invitrogen, Carlsbad, USA) and a primary
rabbit mAb directed against murine histone protein H2B (Abcam,
Cambridge, UK) for 30 min, followed by incubation with
secondary goat FITC-labeled anti-rabbit polyclonal antibody
(Abcam). Image acquisition was performed as described above.
Confocal planes covering the whole cell (projection of twenty five
z-planes; z-spacing, 1 mm) were projected, using the maximum-
intensity-projection module of Huygens software (SVI, Hilversum,
Netherlands).
Histochemistry
To determine mast cell activation in vivo, ruthenium red staining
of the cremaster muscle was performed as described previously
[41]. Mast cell activation was assessed in sham-operated control
mice as well as in mice receiving tranexamic acid, e-aminocaproic
acid, aprotinin, cromolyn, MK-886, BN 52021, or drug vehicle
undergoing I/R (30/120 min). Mast cell activation was also
analyzed in control mice with an intrascrotal injection of PBS
supplemented with 0.01% BSA as well as in mice receiving either
cromolyn, MK-886, BN 52021, or drug vehicle undergoing
intrascrotal stimulation with plasmin. As a positive control for mast
cell staining, exteriorized cremaster muscles of untreated mice
were superfused for 30 min with the mast cell activator compound
48/80 (CMP 48/80; 1 mgm l
-1; Sigma Aldrich; n=4 each group).
Thereafter, exteriorized cremaster muscles were superfused for
60 min with a 0.001% solution of ruthenium red (Sigma Aldrich),
respectively. The number of ruthenium red-positive cells was
quantified by light microscopy (objective magnification 10x) in
cremaster muscle whole mounts (10 observation fields per whole
mount) from four individual animals per experimental group in a
blinded manner, respectively.
Immunohistochemistry
To determine the phenotype of transmigrated leukocytes,
immunostaining of paraffin-embedded serial tissue sections of
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with primary rat anti-mouse anti-Ly-6G, anti-CD45 (BD Biosci-
ences, San Jose, CA, USA), or anti-F4/80 (Serotec, Oxford, UK)
IgG antibodies. Then, the paraffin sections were stained with
commercially available immunohistochemistry kits (Ly-6G, CD45,
Super Sensitive Link-Label IHC detection system, BioGenex, San
Ramon, CA, USA; F4/80, Vectastain ABC kit, Vector Labora-
tories, Burlingame, CA, USA), obtaining an easily detectable
reddish or brownish end product, respectively. Finally, the sections
were counterstained with Mayer’s hemalaun. The number of
extravascularly localized Ly-6G-, CD45-, or F4/80-positive cells
was quantified by light microscopy (objective magnification 40x)
on three sections (10 observation fields per section) from six
individual animals per experimental group in a blinded manner,
respectively. The number of transmigrated Ly-6G-positive cells
(neutrophils/monocytes) and F4/80-positive cells (monocytes/
macrophages) is expressed as the percentage of total CD45-
positive leukocytes.
Flow cytometry
BMMCs were incubated with primary rabbit mAb directed
against murine histone protein H2B (Abcam, Cambridge, UK) for
30 min on ice. After washing, cells were incubated for 30 min on
ice with a secondary goat FITC-labeled anti-rabbit polyclonal
antibody (Abcam). Anticoagulated whole blood samples were
incubated for 30 min at room temperature with different
concentrations (1 and 100 ng ml
21) of plasmin or PMA
(10 ng ml
21) as a positive control and with PBS supplemented
with 0.01% BSA used as vehicle control. After washing, samples
were incubated with fluorescence-labeled monoclonal antibodies
(mAb) directed against either CD11b/Mac-1 (FITC) or CD62L/
L-selectin (PE; BD Biosciences, San Jose, CA) on ice. Stained cells
were analyzed on a flow cytometer (FACSort, Becton Dickinson,
Franklin Lakes, NJ, USA). Approximately 10,000 gated events
were collected in each analysis.
RT-PCR
5-lipoxygenase (5-LO) and lyso-PAF-acetyltransferase (LPCAT)
mRNA expression: Total RNA contents were extracted using the
RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) according to
the manufacturers’ instruction manual. Reverse transcription was
carried out using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Hamburg, Germany). Real time PCR
was conducted with the TaqManH Universal Master Mix Kit in a
7300 Real-Time PCR System (all Applied Biosystems, Hamburg,
Germany). Primers and probes were obtained from ABI (Foster
City, California, USA) TaqMan Gene Expression Assay catalog
(5-LO: Mm01182750_m1; LPCAT: Mm00557141_m1) and from
Biomers (Ulm, Germany) GAPDH forward: 59-tgc agt ggc aaa gtg
gag at-39. GAPDH reverse: 59- tgc cgt gag tgg agt cat act-39 (bp 1-
1254; gene bank accession number NM_008084); GAPDH
TaqMan probe: 59- FAM –cca tca acg acc cct tca ttg acc tc-
BHQ-39. GAPDH was used as an internal housekeeping gene.
Calculation of the mRNA content was performed by a
mathematical model developed by Pfaffl and collegues [42].
Statistics
Data analysis was performed with a statistical software package
(SigmaStat for Windows, Jandel Scientific, Erkrath, Germany).
Unless otherwise stated, the ANOVA on ranks test followed by the
Student-Newman-Keuls test was used for the estimation of
stochastic probability in intergroup comparisons. Mean values
and SEM are given. P values 0.05 were considered significant.
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